JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Hologic Inc

Gesloten

SectorGezondheidszorg

74.02 0.16

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

73.84

Max

74.1

Belangrijke statistieken

By Trading Economics

Inkomsten

212M

195M

Verkoop

19M

1B

K/W

Sectorgemiddelde

28.98

37.461

EPS

1.08

Winstmarge

19.037

Werknemers

7,063

EBITDA

341M

334M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+5.42% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.3B

16B

Vorige openingsprijs

73.86

Vorige sluitingsprijs

74.02

Nieuwssentiment

By Acuity

25%

75%

51 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Hologic Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 okt 2025, 13:20 UTC

Acquisities, Fusies, Overnames

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

27 mei 2025, 18:46 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

21 okt 2025, 16:36 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Hologic Seen as Prime Take-Private Candidate -- Market Talk

21 okt 2025, 13:05 UTC

Acquisities, Fusies, Overnames

Blackstone, TPG to Buy Hologic for Up to $18.3B

21 okt 2025, 12:50 UTC

Acquisities, Fusies, Overnames

Hologic Plans to File Form 10-K for Fiscal 2025 With the SEC in Late Nov >HOLX

21 okt 2025, 12:49 UTC

Acquisities, Fusies, Overnames

Hologic Does Not Intend to Provide Fincl Guidance for FY26 in Upcoming 4Q Results Release

21 okt 2025, 12:48 UTC

Acquisities, Fusies, Overnames

Hologic Merger Agreement Includes a 45-Day 'Go-Shop' Period >HOLX

21 okt 2025, 12:48 UTC

Acquisities, Fusies, Overnames

Hologic Will Continue to Operate Under the Hologic Name and Brand >HOLX

21 okt 2025, 12:48 UTC

Acquisities, Fusies, Overnames

Hologic Will Maintain Its Headquarters in Marlborough, Massachusetts >HOLX

21 okt 2025, 12:47 UTC

Acquisities, Fusies, Overnames

Blackstone's Private Equity Strategy for Individual Investors Is Also Expected to Invest as Part of Transaction

21 okt 2025, 12:46 UTC

Acquisities, Fusies, Overnames

Blackstone and TPG Secured Committed Financing From Citi, Bank of Amer, Barclays, Royal Bank of Canada and SMBC

21 okt 2025, 12:46 UTC

Acquisities, Fusies, Overnames

Blackstone and TPG Have Secured Committed Financing for the Transaction >HOLX

21 okt 2025, 12:45 UTC

Acquisities, Fusies, Overnames

Hologic: Transaction Includes Significant Minority Investments From Subsidiary of Abu Dhabi Investment Authority and an Affil of GIC >HOLX

21 okt 2025, 12:45 UTC

Acquisities, Fusies, Overnames

Hologic: Purchase Price Represents Premium of About 46% to Closing Price on May 23 >HOLX

21 okt 2025, 12:45 UTC

Acquisities, Fusies, Overnames

Hologic: Non-tradable CVR Would Be Issued to Holders at Closing and Paid Following Achievement of Certain Global Rev Goals for Breast Health Business in FY26, FY27

21 okt 2025, 12:44 UTC

Acquisities, Fusies, Overnames

Blackstone and TPG Will Acquire Hologic Shrs for $76/Shr in Cash Plus Non-Tradable CVR to Get Up to $3/Shr for Total of Up to $79/Shr in Cash >HOLX

21 okt 2025, 12:42 UTC

Acquisities, Fusies, Overnames

Hologic: Transaction Will Help Strengthen Leadership in Women's Health and Accelerate Growth >HOLX

21 okt 2025, 12:42 UTC

Acquisities, Fusies, Overnames

Hologic to Be Acquired by Funds Managed by Blackstone Deal and TPG in Deal With Enterprise Value of Up to $18.3 B >BX HOLX

27 mei 2025, 20:07 UTC

Acquisities, Fusies, Overnames

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27 mei 2025, 19:06 UTC

Acquisities, Fusies, Overnames

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27 mei 2025, 18:26 UTC

Acquisities, Fusies, Overnames

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Peer Vergelijking

Prijswijziging

Hologic Inc Prognose

Koersdoel

By TipRanks

5.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 78 USD  5.42%

Hoogste 94 USD

Laagste 69 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hologic Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

13 ratings

3

Buy

10

Hold

0

Sell

Technische score

By Trading Central

52.69 / 58.605Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

51 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat